University of Manchester
manchester.ac.ukTotal trials
200
Active
44
Phase 3
4
Total enrollment
705,624
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII | — | — | — | — | — | 1 | |
| Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene | — | — | — | — | — | 1 | |
| Cord blood transplantation + conditioning + granulocytes of variable days according to study design | — | — | — | — | — | 1 | |
| Granulocytes | — | — | — | — | — | 1 | |
| Camzyos | — | — | — | — | — | 1 |
Next readouts
- 2024-10-30
- 2026-06
- 2028-07
- 2028-10
- 2028-12-31
Top conditions
- Depression11
- Anxiety9
- Psychosis8
- Cancer6
- Cardiovascular Diseases5
- Stroke5
- Dysphagia4
- Obesity4
Frequently asked questions about University of Manchester
- How many clinical trials does University of Manchester have on ClinicalTrials.gov?
- University of Manchester is listed as the lead sponsor on 200 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Manchester's trials are in Phase 3?
- 4 of University of Manchester's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University of Manchester focus on?
- University of Manchester's most-studied conditions on ClinicalTrials.gov are Depression, Anxiety, Psychosis, Cancer, Cardiovascular Diseases.
- When are University of Manchester's next clinical trial readouts?
- University of Manchester has 5 upcoming primary-completion readouts tracked here; the soonest is “Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA”, expected around 2024-10-30.